Skip to content
ChickenStockChickenStock
Research069620
Daewoong Pharma logo

Daewoong Pharma (069620) stock

KOSPI · Pharmaceuticals

KRW 101,300-0.59%(-600)

As of Nov 16, 1:05 PM KST

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

6.40x

P/B

1.14x

P/S

0.70x

Earnings

Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.

Quarters and year-to-date
PeriodRevenueOperating profitNet incomeRevenue YoY
Q2 2026Consolidated · Filed Aug 14, 2026KRW 448.5 billionKRW 68.1 billionKRW 19.9 billion+10.6%
Q1 2026Consolidated · Filed May 15, 2026KRW 377.8 billionKRW 22.2 billionKRW 25.5 billion+6.0%
Q4 2025Consolidated · Filed Mar 18, 2026KRW 397.1 billionKRW 43.3 billionKRW 85.7 billion—
Q3 2025Consolidated · Filed Nov 14, 2025KRW 411.8 billionKRW 56.9 billionKRW 47.3 billion+14.9%
Q2 2025Consolidated · Filed Aug 14, 2025KRW 405.4 billionKRW 57.9 billionKRW 40.1 billion+12.5%
Q1 2025Consolidated · Filed May 15, 2025KRW 356.5 billionKRW 38.7 billionKRW 19.8 billion+6.2%
Fiscal years
PeriodRevenueOperating profitNet incomeRevenue YoY
FY2025Consolidated · Filed Mar 18, 2026KRW 1.6 trillionKRW 196.8 billionKRW 192.9 billion—
FY2024Consolidated · Filed Aug 14, 2025KRW 1.4 trillionKRW 147.9 billionKRW 23.3 billion—
  • Q2 2026 is computed as H1 2026 minus Q1 2026.
  • Q4 2025 is computed as FY2025 minus 9M 2025.
  • Q3 2025 is computed as 9M 2025 minus H1 2025.
  • Q2 2025 is computed as H1 2025 minus Q1 2025.
Original filing (DART)

Short selling and securities lending

Short sales as a share of trading value, the reported short position and the securities lending balance.

Short-sale share
14.67%
Of trading value on Nov 13, 2026
Short-sale value
KRW 300 million
Previous 20-day average 16.01%
Net short position
39,955 shares
As of Nov 11, 2026 · reported with a two-trading-day lag
Lending balance
349,971 shares
As of Nov 13, 2026 · 3.02% of listed shares
Recent short-sale days
DateShareValue
Nov 13, 202614.67%KRW 300 million
Nov 12, 202618.07%KRW 600 million
Nov 11, 202615.77%KRW 260 million
Nov 10, 20268.95%KRW 150 million
Nov 9, 20267.10%KRW 160 million
Nov 6, 20268.90%KRW 220 million
Nov 5, 202614.37%KRW 460 million
Nov 4, 202627.49%KRW 560 million
Nov 3, 202621.17%KRW 440 million
Nov 2, 202616.59%KRW 230 million

The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.

Daewoong Pharma (069620) stock information

KOSPI

Daewoong Pharma (069620) is listed on KOSPI. Its market capitalization is about KRW 1.2 trillion. On trailing-twelve-month earnings the P/E ratio is 6.4, and the P/B ratio is 1.14. Return on equity is 17.9%. These figures are computed in-house from official filings and are reference information only.

Daewoong Pharma — frequently asked questions

What is the P/E ratio of Daewoong Pharma (069620)?
On a trailing-twelve-month basis, 069620 trades at a P/E ratio of 6.4. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Daewoong Pharma?
069620 has a market capitalization of about KRW 1.2 trillion. The figure moves with the share price and is refreshed each trading day.
Does Daewoong Pharma pay a dividend?
069620 has a dividend yield of about 0.59%, based on disclosed payment history. Dividend policy can change; this is reference information only.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.